Pharma: Other news to note

Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, said the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted against the approval of the use of Xarelto (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome in combination with standard antiplatelet therapy.